Literature DB >> 4064345

In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.

D Armanini, I Karbowiak, A Goi, F Mantero, J W Funder.   

Abstract

We have established a sensitive and specific radioreceptor assay for androgen receptor active materials in plasma, using tritiated methyltrienolone ([3H]R1881) as tracer, and spayed mouse kidney cytosol receptor as the binding species. On radioreceptor assay, plasma from mice chronically administered spironolactone contained approximately 10 times higher levels of androgen receptor active material than from mice administered potassium canrenoate. In parallel bioassays (antagonism of the effect of testosterone on seminal vesicle weight), spironolactone was greater than 4 times as potent an antiandrogen as potassium canrenoate. Administered potassium canrenoate circulates as canrenoic acid, in equilibrium with its lactonized congener canrenone. Since over 80% of administered spironolactone is irreversibly converted to canrenone/canrenoic acid, its much higher anti-androgen activity on radioreceptor assay and bioassay may point to the generation of unidentified, minor metabolites with very high affinity for androgen receptors and/or a very long plasma half-life.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064345     DOI: 10.1111/j.1365-2265.1985.tb01090.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.

Authors:  D Armanini; C Scaroni; M J Mattarello; C Fiore; N Albiger; P Sartorato
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

Review 2.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 3.  Aldosterone receptor antagonists: biology and novel therapeutic applications.

Authors:  Paolo Magni; Marcella Motta
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

Review 4.  Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.

Authors:  Andrew S Brem; Rujun Gong
Journal:  Clin Sci (Lond)       Date:  2015-05       Impact factor: 6.124

Review 5.  Aldosterone receptor antagonists: biology and novel therapeutical applications.

Authors:  P Magni; M Motta
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

6.  Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.

Authors:  C Sabbadin; A Andrisani; M Zermiani; G Donà; L Bordin; E Ragazzi; M Boscaro; G Ambrosini; D Armanini
Journal:  J Endocrinol Invest       Date:  2016-04-12       Impact factor: 4.256

7.  Microalbuminuria and hypertension in pregnancy: role of aldosterone and inflammation.

Authors:  Decio Armanini; Guido Ambrosini; Chiara Sabbadin; Gabriella Donà; Giulio Clari; Luciana Bordin
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-05-31       Impact factor: 3.738

8.  Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist.

Authors:  Javaid Iqbal; Ruth Andrew; Nicholas L Cruden; Christopher J Kenyon; Katherine A Hughes; David E Newby; Patrick W F Hadoke; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

Review 9.  Interfering with mineralocorticoid receptor activation: the past, present, and future.

Authors:  Anne M Dorrance
Journal:  F1000Prime Rep       Date:  2014-08-01

Review 10.  Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy.

Authors:  Chiara Sabbadin; Alessandra Andrisani; Guido Ambrosini; Luciana Bordin; Gabriella Donà; Jacopo Manso; Filippo Ceccato; Carla Scaroni; Decio Armanini
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-23       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.